# A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

> **NCT00700427** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 2017 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** atomoxetine hydrochloride
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00700427
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2011-08
- **Final completion:** 2013-10
- **Target enrollment:** 2017 (ACTUAL)
- **Last updated:** 2014-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00700427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00700427, "A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00700427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*